ChiCTR2000038419 版本V1.2 版本创建时间2020/12/21 01:24:38 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000038419 

最近更新日期:

Date of Last Refreshed on:

2020-12-21 01:23:58 

注册时间:

Date of Registration:

2020-09-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

徐帅医师:请检查伦理审批文件签署的研究实施时间(9月31日?) 缩宫素鼻喷雾剂预防及治疗产后抑郁

Public title:

A randomized controlled clinical trial of intranasal oxytocin to improve postpartum depressive emotion.

注册题目简写:

English Acronym:

研究课题的正式科学名称:

缩宫素鼻喷雾剂预防及治疗产后抑郁

Scientific title:

A randomized controlled clinical trial of intranasal oxytocin to improve postpartum depressive emotion.

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

徐帅 

研究负责人:

高晓林 

Applicant:

Shuai Xu 

Study leader:

Xiaolin Gao 

申请注册联系人电话:

Applicant telephone:

+86 13573765386

研究负责人电话:

Study leader's telephone:

+86 17660082688

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

bohetang_2005@163.com

研究负责人电子邮件:

Study leader's E-mail:

huayi1978@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省济南市北园大街247号

研究负责人通讯地址:

山东省济南市北园大街247号

Applicant address:

247 Beiyuan Street, Ji'nan, Shandong, China

Study leader's address:

247 Beiyuan Street, Ji'nan, Shandong, China

申请注册联系人邮政编码:

Applicant postcode:

250033

研究负责人邮政编码:

Study leader's postcode:

250033

申请人所在单位:

山东大学第二医院

Applicant's institution:

The Second Hospital of Shandong University

研究负责人所在单位:

山东大学第二医院

Affiliation of the Leader:

The Second Hospital of Shandong University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KYLL-2020(LW)-052

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山东大学第二医院科研伦理委员会

Name of the ethic committee:

Research Ehics Committee of the Second Hospital of Shandong University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-09-30 00:00:00

伦理委员会联系人:

王传新

Contact Name of the ethic committee:

Chuanxin Wang

伦理委员会联系地址:

山东省济南市北园大街247号

Contact Address of the ethic committee:

247 Beiyuan Street, Ji'nan, Shandong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

山东大学第二医院

Primary sponsor:

The Second Hospital of Shandong University

研究实施负责(组长)单位地址:

山东省济南市北园大街247号

Primary sponsor's address:

247 Beiyuan Street,Ji'nan, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Ji'nan

单位(医院):

山东大学第二医院

具体地址:

北园大街247号

Institution
hospital:

The Second Hospital of Shandong University

Address:

247 Beiyuan Street

经费或物资来源:

山东大学横向课题

Source(s) of funding:

Horizontal Project of Shandong University

Target disease:

Postpartum depression

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

研究产后应用鼻吸缩宫素对产妇抑郁情绪评分的影响;对产后子宫复旧的影响;对产后出血量的影响  

Objectives of Study:

To study the effect of nasal oxytocin on the postpartum depressive emotion by using Edinburgh Postnatal depression Scale To study the effect of nasal oxytocin on the involution of uterus To study the effect of nasal oxytocin on the amount of postpartum bleeding.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)足月(36-42周)、单胎妊娠;
(2)18岁≤产妇年龄≤45岁;
(3)可以充分交流沟通;
(4)知情同意自愿参加并签署知情同意书。

Inclusion criteria

(1)Full-term (36-42 weeks), singleton pregnancy
(2)Aged 18 to 45 years
(3)Can communicate freely;
(4)Voluntarily signing the informed consent

排除标准:

(1)既往有精神疾病、抑郁患者;
(2)合并颅脑损伤;
(3)严重心、肺、肝、肾功能异常;
(4)产妇存在严重的产科并发症或严重基础疾病;
(5)新生儿存在严重的遗传疾病或先天性疾病;
(6)研究者认为不适宜参加临床试验者。
(6)近三月内参加其他药物临床研究者;
(7)研究者认为不适宜参加临床试验者。

Exclusion criteria:

(1)Previous mental illness or depression;
(2)Combined with craniocerebral injury;
(3)Serious abnormal heart, lung, liver and kidney function;
(4)Combined with serious obstetric complication or serious foundational diseases;
(5)Infants with congenital or inheritance diseases.
(6)The researchers considered it inappropriate to participate in this clinical trial.

研究实施时间:

Study execute time:

From 2020-09-30 00:00:00 To 2021-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-09-30 00:00:00 To 2021-08-31 00:00:00  

干预措施:

Interventions:

组别:

试验组

样本量:

20

Group:

Experimental group

Sample size:

干预措施:

鼻吸缩宫素

干预措施代码:

Intervention:

nasal oxytocin

Intervention code:

组别:

安慰机组

样本量:

20

Group:

Placebo group

Sample size:

干预措施:

生理盐水

干预措施代码:

Intervention:

saline solution

Intervention code:

组别:

空白对照组

样本量:

20

Group:

Blank control group

Sample size:

干预措施:

常规产后护理

干预措施代码:

Intervention:

standard postpartum care

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

济南 

Country:

China 

Province:

Shadong 

City:

Ji'nan 

单位(医院):

山东大学第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Hospital of Shandong University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

爱丁堡产后抑郁量表

指标类型:

主要指标

Outcome:

Edinburgh Postnatal Depression Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

VAS数字疼痛评分量表

指标类型:

主要指标

Outcome:

VAS numerical rating scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

产后出血量

指标类型:

次要指标

Outcome:

postpartum haemorrhage

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

子宫体积

指标类型:

次要指标

Outcome:

uterine size

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

副反应

指标类型:

附加指标

Outcome:

side effect

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 45 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

由不参与此试验的研究员使用随机软件生成随机数,随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

The researcher who was blind to the study provids the random number sheet. Based on a computer-generated random number sheet, patients were randomly allocated to received different oxytocin dose regimens.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

发表6个月内,上传至所发表期刊;ResMan, http://www.medresman.org.cn.

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

6 monthsafter publication,submit to the journal; ResMan, http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据通过CRF表格记录,并由试验助理人员负责管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The primary data are collected on Case-Report Form(CRF),which will be saved and managed by an assistant.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-09-22 07:53:37